What does a modified-Fibonacci dose-escalation actually correspond to?
Open Access
- 23 July 2012
- journal article
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 12 (1) , 103
Abstract
In most phase I oncology trials, it is often stated that the dose increments follow a “modified-Fibonacci sequence”. This term, however, is vague.Keywords
This publication has 10 references indexed in Scilit:
- Translation of Innovative Designs Into Phase I TrialsJournal of Clinical Oncology, 2007
- Phase 1 Dose-Finding Trials and FibonacciClinical Cancer Research, 2006
- Choosing a Phase I Design2005
- Modified Fibonacci SearchJournal of Clinical Oncology, 2003
- Cancer phase I clinical trials: efficient dose escalation with overdose controlStatistics in Medicine, 1998
- Accelerated Titration Designs for Phase I Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1997
- Phase I trial design: Are new methodologies being put into practice?Annals of Oncology, 1996
- Continual Reassessment Method: A Likelihood Approach1996
- Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer AgentsJNCI: Journal of the National Cancer Institute, 1993
- Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug DevelopmentJNCI: Journal of the National Cancer Institute, 1990